Biosimilars, high-yielding CHO cell lines, scalable processes

We offer both ready-to-use and on-request biosimilar cell lines and production processes, with flexible deal terms.
With over 20 years of experience, we utilize state-of-the-art technology and employ top-notch experts in process science, manufacturing, analytics, and quality to develop robust and high-yielding cell lines in record time.

What we offer

  • Over a dozen ready-to-use cell lines that produce biosimilars, including pembrolizumab, trastuzumab, rituximab, adalimumab, and more
  • With many more biosimilars in development including monoclonal antibodies, fertility-related hormones (FSH, HCG), growth hormones, and EPOs
  • Suspension-based, stable, monoclonal, CHO cell lines
  • GMP-compliant, master cell banks available
  • All supporting documentation for regulatory submissions
  • Scaleable GMP-ready Upstream and Downstream processes
  • Chemically defined media and feeds, both proprietary and commercial